Injection of hydrogel spacer increased intrafractional prostate motion during volumetric modulated arc therapy-stereotactic body radiation therapy for prostate cancer

Subaru Sawayanagi
University of Tokyo Hospital: Tokyo Daigaku Igakubu Fuzoku Byoin

Hideomi Yamashita (yamachen07291973@yahoo.co.jp)
University of Tokyo Hospital: Tokyo Daigaku Igakubu Fuzoku Byoin

Mami Ogita
University of Tokyo Hospital: Tokyo Daigaku Igakubu Fuzoku Byoin

Yuki Nozawa
University of Tokyo Hospital: Tokyo Daigaku Igakubu Fuzoku Byoin

Yuichi Watanabe
University of Tokyo Hospital: Tokyo Daigaku Igakubu Fuzoku Byoin

Toshikazu Imae
University of Tokyo Hospital: Tokyo Daigaku Igakubu Fuzoku Byoin

Osamu Abe
University of Tokyo Hospital: Tokyo Daigaku Igakubu Fuzoku Byoin

Research Article

**Keywords:** prostate cancer, stereotactic body radiation therapy, intrafractional prostate motion, transperineal ultrasound, hydrogel spacer

**DOI:** https://doi.org/10.21203/rs.3.rs-387231/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

The aim of this study was to clarify the association between intrafractional prostate shift and hydrogel spacer.

Methods

Thirty-eight patients who received definitive volumetric modulated arc therapy (VMAT)-stereotactic body radiation therapy (SBRT) for prostate cancer with prostate motion monitoring in our institution in 2018–2019 were retrospectively evaluated. In order to move the rectum away from the prostate, hydrogel spacer (SpaceOAR system, Boston Scientific, Marlborough, the United States) injection was proposed to the patients as an option in case of meeting the indication of use. We monitored intrafractional prostate motion by using a 4-dimensional (4D) transperineal ultrasound (US) device: the Clarity 4D ultrasound system (Elekta AB). The deviation of the prostate was monitored in each direction: superior-inferior (SI), left-right (LR), and anterior-posterior (AP). We also calculated the vector length (VL). The maximum intrafractional displacement (MID) per fraction for each direction was detected and mean of MIDs was calculated per patient. The MIDs in the non-spacer group and the spacer group were compared using the unpaired t-test.

Results

We reviewed 33 fractions in eight patients as the spacer group and 148 fractions in 30 patients as the non-spacer group. The superior MID was $0.47 \pm 0.07$ (mean $\pm$ SE) mm vs. $0.97 \pm 0.24$ mm ($P = 0.014$), the inferior MID was $1.07 \pm 0.11$ mm vs. $1.03 \pm 0.25$ mm ($P = 0.88$), the left MID was $0.74 \pm 0.08$ mm vs. $0.87 \pm 0.27$ mm ($P = 0.55$), the right MID was $0.67 \pm 0.08$ mm vs. $0.92 \pm 0.21$ mm ($P = 0.17$), the anterior MID was $0.45 \pm 0.06$ mm vs. $1.16 \pm 0.35$ mm ($P = 0.0023$), and the posterior MID was $1.57 \pm 0.17$ mm vs. $1.37 \pm 0.22$ mm ($P = 0.56$) in the non-spacer group and the spacer group, respectively. The max of VL was $2.24 \pm 0.19$ mm vs. $2.89 \pm 0.62$ mm ($P = 0.19$), respectively.

Conclusions

Our findings suggest that intrafractional prostate motion during VMAT-SBRT was larger in patients with hydrogel spacer injection in the superior and anterior directions.

Background

External beam radiation therapy (EBRT) is recognized as one of the primary treatment options for patients with prostate cancer (PCa) (1, 2). Intensity modulated radiation therapy (IMRT) with image-guided radiation therapy (IGRT) technique is currently the gold standard for EBRT. A low $\alpha/\beta$ ratio of PCa has encouraged hypofractionation and stereotactic body radiation therapy (SBRT), or extreme hypofractionation, which is currently considered as a promising option of EBRT (3, 4). While higher
quality of positioning is required in SBRT to optimize treatments, it is known that organs in pelvis including prostate are shifting under the influence of rectal volume, bladder volume, and change of muscle tension among other things (5–12). These intrafractional uncertainties possibly affect the dose distributions (13, 14).

Less is known about risk factors related to intrafractional prostate motion. While the variability in location of external skin markers relative to internal anatomy in obese patients caused a significant difference in terms of interfractional prostate shift (15), there was no relationship between body mass index (BMI) and intrafractional prostate motion (16). It was reported that the shorter the maximum rectal diameter is, the less the intrafractional prostate motion is (17).

The injection of hydrogel spacer between the prostate and the rectum has been introduced for RT for PCa to separate the prostate from the anterior wall of the rectum, which contributes to reducing the RT dose of the rectum. It was shown that the insertion of hydrogel spacer did not greatly limit interfractional and intrafractional prostate displacements (18–20). We hypothesized that the hydrogel spacer potentially implicates the prostate variability during RT. The aim of this study was to clarify the association between the intrafractional prostate shift and the hydrogel spacer.

**Methods**

A total of 38 patients with histologically confirmed prostate cancer who received definitive volumetric modulated arc therapy (VMAT)-SBRT with prostate motion monitoring with or without androgen deprivation therapy (ADT) for PCa in our institution in 2018–2019 were retrospectively evaluated. The study was reviewed and approved by the institutional review board and ethics committee. Examination number was 3372.

**Radiotherapy**

A total dose of 36.25-40 Gy in five fractions was prescribed to 95% of the planning target volume (PTV) every other weekday. All patients received CT scans which were reconstructed 1-mm-thick slices with a full bladder for treatment planning. A rectal enema was prescribed before simulation and before each treatment session to empty the contents of the rectum. The clinical target volume (CTV) consisted of prostate with or without seminal vesicles according to the risk classification of the NCCN guidelines version 1.2018. The CTV was extended by 5mm in every direction except posterior with 3mm extension to generate the PTV. We used Monaco (Elekta AB, Stockholm, Sweden) as the treatment planning system. In order to move the rectum away from the prostate, the hydrogel spacer (SpaceOAR system, Boston Scientific, Marlborough, the United States) was transperineally injected into the recto-prostatic space of patients who hoped to receive it in case of meeting the indication of use. KV cone beam CT (CBCT) scans were acquired after the setup before each treatment session to reduce the interfraction error of patient positioning.
Intrafraction motion of the prostate was monitored by a 4-dimensional (4D) transperineal ultrasound (US) device: the Clarity 4D ultrasound system (Elekta AB) with an autoscanning perineal US probe. We regarded the prostate position when CBCT scans finished as the baseline position. Monitoring time was defined as the time from the end of CBCT to the end of radiation. The deviation of the prostate from the baseline position was monitored as a function of time along the three directions: superior-inferior (SI), left-right (LR), and anterior-posterior (AP). We also calculated the vector length (VL) at each point in time.

Large spike-like prostate displacement was seen during couch shift for patient position adjustment in some fractions (Fig. 1) though the prostate position we evaluated was relative to the couch position. We excluded these displacements from analyses because all patients immediately recovered from this error before the start of radiation. The maximum intrafractional displacement (MID) per fraction for each direction was detected and mean of MIDs was calculated per patient. The Stroom formula \( (21) \) \( = 2.0 \Sigma + 0.7 \sigma \) and the van Herk formula \( (22) \) \( = 2.5 \Sigma + 0.7 \sigma \) were used to calculate the CTV-PTV margin derived from intrafractional error, where \( \Sigma \) is the systematic error and \( \sigma \) is the random error.

**statistical analysis**

Differences in characteristic variables between patients without spacer and those with spacer were tested using the \( \chi^2 \)-test for categorical variables and the unpaired t-test for continuous variables. In this study, the volume from the slice 1 cm above the highest part of the PTV to the slice 1 cm below the lowest part of the PTV in axial slices was considered as rectum volume. Bladder volume in this context included internal urine. The MIDs in the non-spacer group and the spacer group were compared using the unpaired t-test. Multiple regression analysis was used to detect risk factors related to intrafractional prostate motion. All statistical analyses were two-sided and performed using R, version 4.0.3. Results were considered statistically significant at \( P < 0.05 \).

**Results**

**patient characteristics**

We reviewed 33 fractions in eight patients as the spacer group and 148 fractions in 30 patients as the non-spacer group. The baseline patient characteristics were presented in Table 1. There was no statistically significant difference between the two groups except for rectal volume. The median age was 73 (58–85) and 79 (66–84) years \( (P = 0.22) \) and the mean monitoring time was 275 ± 42 (mean ± SD) and 279 ± 33 seconds \( (P = 0.82) \) in the non-spacer group and the spacer group, respectively. Twenty-one patients (70.0%) in the non-spacer group and six patients (75.0%) in the spacer group received neoadjuvant ADT \( (P = 0.99) \), respectively. The mean BMI was 23.5 ± 2.7 and 23.6 ± 3.4 kg/m\(^2\) in the non-spacer group and the spacer group, respectively \( (P = 0.93) \). Nine patients (30.0%) in the non-spacer and one patient (12.5%) in the spacer group underwent abdominal surgery before RT, respectively \( (P = 0.65) \). The mean volume of prostate (non-spacer vs. spacer group, 31.1 ± 12.4 cc vs. 25.0 ± 9.2 cc, \( P = 0.22 \)) and bladder (277.1 ± 169.2 cc vs. 205.2 ± 77.9 cc, \( P = 0.26 \)) measured on planning CT in each group was not
significantly different. The rectum volume on planning CT in the non-spacer group was larger than the spacer group (55.4 ± 15.5 cc vs. 43.4 ± 9.0 cc, P = 0.047).
### Table 1
Baseline patient characteristics

| Parameter                              | Non-spacer group | Spacer group | P value |
|----------------------------------------|------------------|--------------|---------|
|                                        | N= 30            | N= 8         |         |
| Age, years, median (range)             | 73 (58–85)       | 79 (66–84)   | 0.22b   |
| Body mass index, mean ± SD             | 23.5 ± 2.7       | 23.6 ± 3.4   | 0.93b   |
| Clinical T stage, n (%)                |                  |              | 0.78c   |
| 1c                                     | 6 (20%)          | 3 (37.5%)    |         |
| 2a                                     | 13 (43.3%)       | 2 (25.0%)    |         |
| 2b                                     | 2 (6.7%)         | 1 (12.5%)    |         |
| 2c                                     | 5 (16.7%)        | 2 (25.0%)    |         |
| 3a                                     | 1 (3.3%)         | 0 (0%)       |         |
| 3b                                     | 2 (6.7%)         | 0 (0%)       |         |
| 4                                      | 1 (3.3%)         | 0 (0%)       |         |
| Mean monitoring time, seconds, mean ± SD | 275 ± 42         | 279 ± 33     | 0.82b   |
| Neoadjuvant ADT, n (%)                 |                  |              | 0.99c   |
| No                                     | 9 (30.0%)        | 2 (25.0%)    |         |
| Yes                                    | 21 (70.0%)       | 6 (75.0%)    |         |
| History of abdominal surgery, n (%)    |                  |              | 0.65c   |
| No                                     | 21 (70.0%)       | 7 (87.5%)    |         |
| Yes                                    | 9 (30.0%)        | 1 (12.5%)    |         |
| Prostate volume*, cc, mean ± SD        | 31.1 ± 12.4      | 25.0 ± 9.2   | 0.22b   |
| Rectum volume*, cc, mean ± SD          | 55.4 ± 15.5      | 43.4 ± 9.0   | 0.047b† |
| Bladder volume*, cc, mean ± SD         | 277.1 ± 169.2    | 205.1 ± 77.9 | 0.26b   |

*Abbreviations: ADT androgen deprivation therapy, SD standard deviation*

*Measured on planning CT

*aFrom the slice 1 cm above the PTV to the slice 1 cm below the PTV in axial slices

bBy unpaired t-test
The comparison of MID for each direction and the max of intrafractional VL between the two groups was presented in Table 2 and the boxplots of them were shown in Fig. 2. The superior MID was 0.47 ± 0.07 (mean ± SE) mm vs. 0.97 ± 0.24 mm (P = 0.014), the inferior MID was 1.07 ± 0.11 mm vs. 1.03 ± 0.25 mm (P = 0.88), the left MID was 0.74 ± 0.08 mm vs. 0.87 ± 0.27 mm (P = 0.55), the right MID was 0.67 ± 0.08 mm vs. 0.92 ± 0.21 mm (P = 0.17), the anterior MID was 0.45 ± 0.06 mm vs. 1.16 ± 0.35 mm (P = 0.0023), and the posterior MID was 1.57 ± 0.17 mm vs. 1.37 ± 0.22 mm (P = 0.56) in the non-spacer group and the spacer group, respectively. The max of VL was 2.24 ± 0.19 mm vs. 2.89 ± 0.62 mm (P = 0.19), respectively. The superior and anterior MIDs were smaller in the non-spacer group, while the other MIDs and VL were not significantly different in the two groups.

**Table 2**

Mean of the maximum intrafractional displacements per patient

| Direction | Non-spacer group | Spacer group | P value<sup>a</sup> |
|-----------|-----------------|--------------|-------------------|
|           | N = 30          | N = 8        |                   |
| mm, Mean ± SE | mm, Mean ± SE |              |                   |
| Superior  | 0.47 ± 0.07     | 0.97 ± 0.24  | 0.014†            |
| Inferior  | 1.07 ± 0.11     | 1.03 ± 0.25  | 0.88              |
| Left      | 0.74 ± 0.08     | 0.87 ± 0.27  | 0.55              |
| Right     | 0.67 ± 0.08     | 0.92 ± 0.21  | 0.17              |
| Anterior  | 0.45 ± 0.06     | 1.16 ± 0.35  | 0.0023†           |
| Posterior | 1.57 ± 0.17     | 1.37 ± 0.22  | 0.56              |
| Vector length | 2.24 ± 0.19     | 2.89 ± 0.62  | 0.19              |

Abbreviations: SE standard error

<sup>a</sup>By unpaired t-test

<sup>†</sup>Statistically significant

**motion analysis**

**multivariate analysis**
The results of multivariate analyses for MIDs for each direction were shown in Table 3. We included age, spacer injection, rectum volume, and the duration of monitoring as explanatory variables. Spacer injection was the independent risk factor of superior and anterior MIDs. There was no independent risk factor of inferior, left, right, and posterior MIDs and maximum VL.
### Table 3
Multivariate analyses for maximum intrafractional displacement

|                        | Regression coefficient (95% CI)          | P-value$^a$ |
|------------------------|-----------------------------------------|-------------|
| **Superior MID**       |                                         |             |
| Age (continuous)       | -0.012 (-0.036-0.012) per year         | 0.31        |
| Spacer injection       |                                         | 0.014†      |
| Non-spacer             | Reference                               |             |
| Spacer                 | 0.546 (0.118–0.975)                     |             |
| Rectum volume (continuous) | 0.001 (-0.001-0.013) per cc         | 0.80        |
| Monitoring time (continuous) | 0.001 (-0.003-0.005) per second | 0.66        |
| **Inferior MID**       |                                         |             |
| Age (continuous)       | 0.026 (-0.003-0.055) per year          | 0.082       |
| Spacer injection       |                                         | 0.31        |
| Non-spacer             | Reference                               |             |
| Spacer                 | -0.263 (-0.783-0.256)                  |             |
| Rectum volume (continuous) | -0.011 (-0.025-0.002) per cc       | 0.10        |
| Monitoring time (continuous) | 0.000 (-0.005-0.005) per second | 0.99        |
| **Left MID**           |                                         |             |
| Age (continuous)       | 0.011 (-0.015-0.038) per year          | 0.39        |
| Spacer injection       |                                         | 0.70        |
| Non-spacer             | Reference                               |             |
| Spacer                 | 0.089 (-0.382-0.560)                   |             |
| Rectum volume (continuous) | 0.000 (-0.012-0.013) per cc         | 0.98        |
| Monitoring time (continuous) | 0.000 (-0.005-0.004) per second | 0.84        |
| **Right MID**          |                                         |             |
| Age (continuous)       | 0.008 (-0.015-0.031) per year          | 0.48        |
| Spacer injection       |                                         | 0.23        |
| Non-spacer             | Reference                               |             |
| Spacer                 | 0.245 (-0.161-0.652)                   |             |
|                                      | Regression coefficient (95% CI) | \( P \) value<sup>a</sup> |
|--------------------------------------|---------------------------------|-----------------------------|
| Rectum volume (continuous)           | 0.002 (-0.008-0.013) per cc     | 0.67                        |
| Monitoring time (continuous)         | 0.002 (-0.001-0.006) per second | 0.22                        |
| **Anterior MID**                     |                                 |                             |
| Age (continuous)                     | 0.008 (-0.020-0.036) per year   | 0.57                        |
| Spacer injection                     |                                 | 0.0074<sup>†</sup>          |
| Non-spacer                           | Reference                       |                             |
| Spacer                               | 0.692 (0.199–1.185)             |                             |
| Rectum volume (continuous)           | 0.001 (-0.012-0.014) per cc     | 0.84                        |
| Monitoring time (continuous)         | 0.002 (-0.003-0.006) per second | 0.50                        |
| **Posterior MID**                    |                                 |                             |
| Age (continuous)                     | 0.004 (-0.042-0.049) per year   | 0.87                        |
| Spacer injection                     |                                 | 0.35                        |
| Non-spacer                           | Reference                       |                             |
| Spacer                               | -0.375 (-1.174-0.424)           |                             |
| Rectum volume (continuous)           | -0.012 (-0.033-0.009) per cc    | 0.24                        |
| Monitoring time (continuous)         | 0.002 (-0.006-0.009) per second | 0.65                        |
| **Maximum intrafractional vector length** |                                 |                             |
| Age (continuous)                     | 0.023 (-0.040-0.085) per year   | 0.46                        |
| Spacer injection                     |                                 | 0.42                        |
| Non-spacer                           | Reference                       |                             |
| Spacer                               | 0.441 (-0.664-1.547)            |                             |
| Rectum volume (continuous)           | -0.010 (-0.039-0.019) per cc    | 0.48                        |
| Monitoring time (continuous)         | 0.002 (-0.008-0.012) per second | 0.69                        |

<sup>a</sup>By multiple regression analysis

<sup>†</sup>Statistically significant

<em>Abbreviations: MID maximum intrafracitonal displacement, CI confidence interval</em>
The mean ($\mu$), the systematic error ($\Sigma$), and the random error ($\sigma$) of intrafractional shift of the prostate were $\mu = (-0.43, 0.06, -1.12)$ mm, $\Sigma = (0.91, 0.78, 1.17)$ mm, and $\sigma = (1.24, 1.25, 1.86)$ mm in the SI, LR, and AP directions, respectively in the non-spacer group. In the spacer group, $\mu = (-0.79, 0.18, -0.71)$ mm, $\Sigma = (1.12, 1.01, 1.32)$ mm, and $\sigma = (2.12, 1.21, 2.42)$ mm, respectively. According to the Stroom formula, margins ($M$) were as follows: $M = (2.69, 2.42, 3.64)$ mm in the SI, LR, and AP directions in the non-spacer group, and $M = (3.71, 2.87, 4.34)$ mm in the spacer group. According to the van Herk formula, $M = (3.14, 2.81, 4.23)$ mm in the non-spacer group and $M = (4.27, 3.37, 5.00)$ mm in the spacer group, respectively.

**Discussion**

We investigated the intrafractional prostate motion during VMAT-SBRT for PCa. Calculated margins according to the Stroom formula were larger in the spacer group than the non-spacer group by (1.02, 0.45, 0.70) mm in the SI, LR, and AP directions, respectively. Based on the van Herk formula, calculated margins were larger in the spacer group than the non-spacer group by (1.13, 0.56, 0.77) mm in the SI, LR, and AP directions, respectively.

Errors related to the quality of radiotherapy are categorized into interfractional errors and intrafractional errors. While interfractional errors can be minimized by using high-precision techniques of patient positioning, intrafractional errors caused by organ motion depended on the patient himself and are difficult to be controlled.

Development of monitoring devices has contributed to knowing the intrafractional organ motions. Mah et al. (5) investigated the intrafractional prostate motion of 42 patients with prostate cancer using cine-MRI. They reported that the displacements of prostate (mean ± SD) were $0.0 \pm 3.4$ mm, $0.0 \pm 1.5$ mm, $0.2 \pm 2.9$ mm in the SI, LR, and AP dimensions, respectively. Willoughby et al. (9) used the Calypso 4D localization system which is real-time tracking system with implanted electromagnetic transponders to track the intrafractional shift of prostate. They showed that the average ($\pm$ SD) of the maximum differences in 11 cases were $3.61 \pm 3.13$ mm, $0.91 \pm 0.35$ mm, $3.92 \pm 4.32$ mm in the SI, LR, and AP directions, respectively. Pinkawa et al. (11) demonstrated that the intrafractional displacements of prostate (mean ± SD) were $0.0 \pm 2.0$ mm, $0.2 \pm 1.9$ mm, $0.6 \pm 2.2$ mm in the SI, LR, and AP directions in 32 patients with prostate cancer by using transabdominal US tracking system. Comparable level of the intrafractional prostate motion with these studies was seen in our study. The average ($\pm$ SE) of the maximum vector displacement was $2.24 \pm 0.19$ mm and $2.89 \pm 0.62$ mm in the non-spacer and the spacer group, respectively.

Shihono et al. (12) suggested the patient population-based margin according to the van Herk formula is as follows: $1.10$ mm, $1.25$ mm, and $1.33$ mm in the SI, LR, and AP directions, respectively. They used the Clarity system just like our study. We demonstrated the larger margins calculated based on our population; $3.14$ mm, $2.81$ mm, $4.23$ mm in the non-spacer group and $4.27$ mm, $3.37$ mm, $5.00$ mm in the spacer group. The difference is probably ascribed to the fact that Shihono et al. may have used mean intrafractional motion for margin calculation, whereas we used maximum intrafractional motion.
Knowledge about parameters related to intrafractional prostate motion is absolutely limited. Brown et al. (16) showed that there was no statistically significant relationship between intrafractional prostate motion and BMI by using linear regression analysis. Oates et al. (17) investigated a relationship between maximum rectal diameter (MRD) and intrafractional prostate motion. They showed with 90% confidence that for a MRD ≤ 3 cm, prostate displacement will be ≤ 5 mm and that for a MRD ≤ 3.5 cm, prostate displacement will be ≤ 5.5 mm. By prescribing a rectal enema and performing CBCT before each treatment session, the variety of MRD may have been minimized in our study. Rectum volume was smaller in the spacer group, which may be caused by the deformation of rectum by the pressure from the anterior direction by the injected hydrogel spacer (Fig. 3). However, rectum volume was not an independent risk factor for prostate displacement in the multivariate analysis. The displacement of prostate was shown to be smaller in step-and-shoot IMRT fractions than in VMAT fractions due to the shorter treatment time of VMAT by Ballhausen et al. (24). In the present study, we treated all patients with VMAT using flattening filter free (FFF) beams and monitoring time from the end of CBCT to the end of radiation was about 4.5 minutes. According to our study, monitoring time did not significantly affect prostate shift.

Picardi et al. (19) showed that hydrogel spacer injection into the recto-prostatic space did not significantly influence the interfraction prostate motion based on the analysis using implanted fiducial markers and CBCT. It was reported that hydrogel spacer insertion significantly reduced the intrafraction rotational shift in the AP direction on cine-MRI by Cuccia et al. (20) and they concluded that hydrogel spacer contributed to limiting prostate intrafractional motion. On the other hand, Juneja et al. (18) showed that the average of the mean intrafractional vector displacement of prostate was significantly larger in patients with hydrogel spacer than those without spacer by analyzing the implanted electromagnetic markers position on kV fluoroscopy. The difference between the two groups was 0.4 mm on their study. In our study, there was no significant difference in maximum VL, whereas superior and anterior MIDs were significantly larger in the spacer group in our study, and the difference between the two groups were 0.5 mm in the superior direction and 0.7 mm in the anterior direction.

The limitation of our study was the fact that the quality of our results depends on the accuracy of the Clarity system. Zhou et al. (24) investigated the discrepancy between the Clarity system and CBCT as the positioning device. The average (± SD) discrepancies were − 0.03 ± 5.22 mm, 0.18 ± 2.87 mm, and 0.31 ± 4.37 mm in the SI, LR, and AP directions, respectively when the Clarity was transperineally used.

**Conclusions**

Our findings suggest that intrafractional prostate motion during VMAT-SBRT was larger in patients with hydrogel spacer injection in the superior and anterior directions. Further studies are expected in order to clarify the cause that prostate in patients with hydrogel spacer tends to move during RT, and to find other factors related to intrafractional prostate motion.

**Abbreviations**
Declarations

Ethics approval and consent to participate

This study was approved by the research ethics committee, University of Tokyo Hospital. Examination number was 3372.

Consent for publication

Patients gave written consent for data collection and analysis.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interests

The authors declare that they have no competing interests in association with this study.

Funding

Not applicable.

Authors’ Contributions

SS collected and assembled the data, drafted the manuscript and critically revised the article for important intellectual content. HY supervised all of the above work. MO, YN, YW, and TI helped to interpret the collected data. OA helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Alisha Huang for careful English proofreading.

References
1. Sanda MG, Cadeddu JA, Kirkby E, Chen RC, Crispino T, Fontanarosa J, Freedland SJ, Greene K, Klotz LH, Makarov D V., Nelson JB, Rodrigues G, Sandler HM, Taplin ME, Treadwell JR. Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2018;199(3):683-690. doi:10.1016/j.juro.2017.11.095

2. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2020:1-20. doi:10.1016/j.eururo.2020.09.042

3. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43(5):1095-1101. doi:10.1016/S0360-3016(98)00438-6

4. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52(1):6-13.

5. Mah D, Freedman G, Milestone B, Hanlon A, Palacio E, Richardson T, Movers B, Mitra R, Horwitz E, Hanks GE. Measurement of intrafractional prostate motion using magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2002;54(2):568-575. doi:10.1016/S0360-3016(02)03008-0

6. Ghilezan MJ, Jaffray DA, Siewerdsen JH, Van Herk M, Shetty A, Sharpe MB, Jafri SZ, Vicini FA, Matter RC, Brabbins DS, Martinez AA. Prostate gland motion assessed with cine-magnetic resonance imaging (cine-MRI). Int J Radiat Oncol Biol Phys. 2005;62(2):406-417. doi:10.1016/j.ijrobp.2003.10.017

7. Boda-Heggemann J, Köhler FM, Wertz H, Ehmann M, Hermann B, Riesenacker N, Küpper B, Lohr F, Wenz F. Intrafraction motion of the prostate during an IMRT session: A fiducial-based 3D measurement with Cone-beam CT. Radiat Oncol. 2008;3(1):1-8. doi:10.1186/1748-717X-3-37

8. Langen KM, Willoughby TR, Meeks SL, Santhanam A, Cunningham A, Levine L, Kupelian PA. Observations on Real-Time Prostate Gland Motion Using Electromagnetic Tracking. Int J Radiat Oncol Biol Phys. 2008;71(4):1084-1090. doi:10.1016/j.ijrobp.2007.11.054

9. Willoughby TR, Kupelian PA, Pouliot J, Shinhara K, Aubin M, Roach M, Skrumeda LL, Balter JM, Litzenberg DW, Hadley SW, Wei JT, Sandler HM. Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006;65(2):528-534. doi:10.1016/j.ijrobp.2006.01.050

10. Kotte ANTJ, Hofman P, Lagendijk JJW, van Vulpen M, van der Heide UA. Intrafraction Motion of the Prostate During External-Beam Radiation Therapy: Analysis of 427 Patients with Implanted Fiducial Markers. Int J Radiat Oncol Biol Phys. 2007;69(2):419-425. doi:10.1016/j.ijrobp.2007.03.029

11. Pinkawa M, Pursch-Lee M, Asadpour B, Gagel B, Piroth MD, Klotz J, Nussen S, Eble MJ. Image-guided radiotherapy for prostate cancer: Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion. Strahlentherapie und Onkol. 2008;184(12):679-685. doi:10.1007/s00066-008-1902-7
12. Sihono DSK, Ehmann M, Heitmann S, von Swietochowski S, Grimm M, Boda-Heggemann J, Lohr F, Wenz F, Wertz H. Determination of Intrafraction Prostate Motion During External Beam Radiation Therapy With a Transperineal 4-Dimensional Ultrasound Real-Time Tracking System. Int J Radiat Oncol Biol Phys. 2018;101(1):136-143. doi:10.1016/j.ijrobp.2018.01.040

13. Adamson J, Wu Q, Yan D. Dosimetric effect of intrafraction motion and residual setup error for hypofractionated prostate intensity-modulated radiotherapy with online cone beam computed tomography image guidance. Int J Radiat Oncol Biol Phys. 2011;80(2):453-461. doi:10.1016/j.ijrobp.2010.02.033

14. Wust P, Joswig M, Graf R, Böhmer D, Beck M, Barelkowski T, Budach V, Ghadjar P. Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy. Strahlentherapie und Onkol. 2017;193(9):700-706. doi:10.1007/s00066-017-1141-x

15. Wong JR, Gao Z, Uematsu M, Merrick S, Machernis NP, Chen T, Cheng CW. Interfractional Prostate Shifts: Review of 1870 Computed Tomography (CT) Scans Obtained During Image-Guided Radiotherapy Using CT-on-Rails for the Treatment of Prostate Cancer. Int J Radiat Oncol Biol Phys. 2008;72(5):1396-1401. doi:10.1016/j.ijrobp.2008.03.045

16. Brown A, Tan A, Cooper S, Fielding A. Obesity does not influence prostate intrafractional motion. J Med Radiat Sci. 2018;65(1):31-38. doi:10.1002/jmrs.255

17. Oates R, Brown A, Tan A, Foroudi F, Lim Joon M, Schneider M, Herschtal A, Kron T. Real-time Image-guided Adaptive-predictive Prostate Radiotherapy using Rectal Diameter as a Predictor of Motion. Clin Oncol. 2017;29(3):180-187. doi:10.1016/j.clon.2016.09.019

18. Juneja P, Kneebone A, Booth JT, Thwaites DJ, Kaur R, Colvill E, Ng JA, Keall PJ, Eade T. Prostate motion during radiotherapy of prostate cancer patients with and without application of a hydrogel spacer: A comparative study. Radiat Oncol. 2015;10(1):4-9. doi:10.1186/s13014-015-0526-1

19. Picardi C, Rouzaud M, Kountouri M, Lestrade L, Vallée JP, Caparrotti F, Dubouloz A, Miralbell R, Zilli T. Impact of hydrogel spacer injections on interfraction prostate motion during prostate cancer radiotherapy. Acta Oncol (Madr). 2016;55(7):834-838. doi:10.3109/0284186X.2015.1128118

20. Cuccia F, Mazzola R, Nicosia L, Figlia V, Giaj-Levra N, Ricchetti F, Rigo M, Vitale C, Mantoan B, De Simone A, Sicignano G, Ruggieri R, Cavalleri S, Alongi F. Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy. Radiat Oncol. 2020;15(1):1-9. doi:10.1186/s13014-020-01622-3

21. Stroom JC, De Boer HCJ, Huizenga H, Visser AG. Inclusion of geometrical uncertainties in radiotherapy treatment planning by means of coverage probability. Int J Radiat Oncol Biol Phys. 1999;43(4):905-919. doi:10.1016/S0360-3016(98)00468-4

22. Van Herk M, Remeijer P, Rasch C, Lebesque J V. The probability of correct target dosage: Dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(4):1121-1135. doi:10.1016/S0360-3016(00)00518-6

23. Ballhausen H, Li M, Ganswindt U, Belka C. Shorter treatment times reduce the impact of intrafractional motion: A real-time 4DUS study comparing VMAT vs. step-and-shoot IMRT for prostate
Figure 1

An example of prostate motion in the superior-inferior direction during single fraction. Red rectangular area means the duration of couch shift. Large spike-like displacement was seen while the couch was shifting.
Figure 2

Boxplots of the maximum intrafractional displacement. a. Mean of superior MID. b. Mean of inferior MID. c. Mean of left MID. d. Mean of right MID. e. Mean of anterior MID. f. Mean of posterior MID. g. Mean of maximum intrafractional vector length. Abbreviations: MID maximum intrafractional displacement †Statistically significant
Figure 3

MRI images of the same patient. a. The image before spacer injection b. The image after spacer injection. Rectum was pressed and deformed by spacer.